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A Mutation in a Skin-Specific Isoform of SMARCAD1
Causes Autosomal-Dominant Adermatoglyphia
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Monogenic disorders offer unique opportunities for researchers to shed light upon fundamental physiological processes in humans. We
investigated a large family affected with autosomal-dominant adermatoglyphia (absence of fingerprints) also known as the ‘‘immigra-
tion delay disease.’’ Using linkage and haplotype analyses, we mapped the disease phenotype to 4q22. One of the genes located in
this interval is SMARCAD1, a member of the SNF subfamily of the helicase protein superfamily.We demonstrated the existence of a short
isoform of SMARCAD1 exclusively expressed in the skin. Sequencing of all SMARCAD1 coding and noncoding exons revealed a hetero-
zygous transversion predicted to disrupt a conserved donor splice site adjacent to the 30 end of a noncoding exon uniquely present in the
skin-specific short isoform of the gene. This mutation segregated with the disease phenotype throughout the entire family. Using amini-
gene system, we found that this mutation causes aberrant splicing, resulting in decreased stability of the short RNA isoform as predicted
by computational analysis and shown by RT-PCR. Taken together, the present findings implicate a skin-specific isoform of SMARCAD1 in
the regulation of dermatoglyph development.Epidermal ridges are characteristic features of the human
skin1 and in wide use in the modern era as almost unsur-
passed identification tools. The physiological role of
epidermal ridges remains controversial. Recent data have
dismissed the theory that fingerprints might improve the
grip by ramping up friction levels.2 Instead, epidermal
ridges might amplify vibratory signals to deeply embedded
nerves involved in fine texture perception.3
The factors underlying the formation of epidermal ridges
during embryonic development and their pattern remain
unknown but are likely to include both genetically deter-
mined traits4 as well as environmental elements5 and to
involve some form of interactions between the mesen-
chymal and the dermal and the epidermal elements. At
24 weeks postfertilization, the epidermal-ridge system
displays an adult morphology6 that remains permanent
without any modification throughout life. The congenital
absence of epidermal ridges is a rare condition known as
adermatoglyphia (ADG). To date only four families with
congenital absence of fingerprints have been described.7–10
In three of these families,7–9 additional features such as
congenital facial milia, skin blisters, and fissures associated
with heat or trauma were reported. A number of more
complex syndromes such as Naegeli-Franceschetti-Jadas-
sohn syndrome (MIM 161000) and dyskeratosis congenita
(MIM 305000) also feature abnormal development of
epidermal ridges,11,12 as detailed in a recent review of the
topic.13
In the present studywe investigated a large Swiss kindred
presenting with autosomal-dominant adermatoglyphia
recently coined as the ‘‘immigration delay disease’’13
because affected individuals report significant difficulties
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302 The American Journal of Human Genetics 89, 302–307, August 1affected members of this family displayed since birth an
absence of fingerprints (Figure 1A); histological analysis13
revealed that this absence was associated with a reduced
number of sweat glands and a sweat test showed a reduced
ability for hand transpiration (Figure 1B).
All affected (n ¼ 9) and healthy (n ¼ 7) family members
or their legal guardian provided written and informed
consent according to a protocol approved by the institu-
tional review board of University Hospital Basel in adher-
ence with the principles of the declaration of Helsinki.
DNA was extracted from peripheral blood lymphocytes.
We initially genotyped all family members by using the
Illumina Human Linkage-12 chip comprising 6000 tagged
SNPs distributed across the genome. Two hundred ng of
DNA were hybridized according to the Infinium II assay
(Illumina, San Diego, CA) and scanned with an Illumina
BeadArray reader. The scanned images were imported
into BeadStudio 3.1.3.0 (Illumina) for extraction and
quality control, with an average call rate of 99.9%.
Multipoint linkage analysiswith the Superlink software14
generated a LOD score of 2.85 at marker rs1509948
(Figure 2). Fine mapping of the disease interval was per-
formed with polymorphic microsatellite markers that
were selected from the National Center for Biotechnology
Infromation (NCBI) database. Genotypes were established
with fluorescently labeled primer pairs (Research Genetics,
Invitrogen, Carlsbad, CA) according to the manufacturer’s
recommendations. PCR products were separated by PAGE
on an automated sequencer (ABI PRISM 3100 Genetic
Analyzer; Applied Biosystems, Foster City, CA), and allele
sizes were determined with Gene Mapper v4.0 software.
Haplotype analysis refined the disease locus to a 5.1 Mb
interval between markers D4S423 and D4S1560 (Figure 2)., Israel; 2Department of Biomedicine, University Hospital Basel, Basel 4051,
51, Switzerland; 4Department of Human Molecular Genetics and Biochem-
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Figure 1. Clinical Features
(A andB)Absenceoffingerprints (A) and reducedhandperspiration
demonstrated by sweat test (B) in a patient with adermatoglyphia.We found the disease interval contained 17 genes. All
coding and noncoding exons of the disease interval genes
were fully sequenced. Initially, nomutation was identified.
We therefore carefully scrutinized all currently available
databases for rare transcripts. We identified one minor
transcript (ENST00000509418, NM_001128430.1), sharing
a common nucleotide sequence with the 30-end of
SMARCAD1 (MIM 612761). SMARCAD1 encodes a protein
that is structurally related to the SWI2/SNF2 superfamily
of DNA-dependent ATPases, which function as catalytic
subunits of chromatin-remodeling complexes and are
consequently considered to be major regulators of tran-
scriptional activity.15 The two SMARCAD1 isoforms differ
in lengths and sites of transcription initiation. The shortest
SMARCAD1 isoform is predicted to contain a unique
50-nontranslated exon (Figure 3A). It is of interest that, in
contrast with the major large isoform, which was found to
be expressed ubiquitously as previously shown,16 the
SMARCAD1 short isoform was mainly identifiable by RT-
PCR in skin fibroblasts and to a lesser extent in keratino-
cytes and esophageal tissue (Figure 4), suggesting that it
might represent an attractive candidate gene for a skin
condition such as ADG.
To assess the possible involvement of SMARCAD1 in
ADG, genomic DNA was amplified by PCR with primer
pairs spanning the entire coding sequence of both
SMARCAD1 isoforms (Table S1, available online) and Taq
polymerase (QIAGEN, Valencia, CA). Cycling conditionsThe Americwere 94C for 2 min followed by three cycles at 94C for
40 s, 61C for 40 s, and 72C for 40 s; three cycles at
94C for 40 s, 59C for 40 s, and 72C for 40 s; three cycles
at 94C for 40 s, 57C for 40 s, and 72C for 40 s; 33 cycles
at 94C for 40 s, 55C for 40 s, and 72C for 40 s; and a final
extension step at 72C for 10 min. DNA was extracted
from gel and purified with QIAquick Gel Extraction kit
(QIAGEN). Direct sequencing of the resulting PCR prod-
ucts with the BigDye terminator system on an automated
sequencer (Applied Biosystems) revealed a heterozygous
G>T transversion in the first intron of the skin-specific
SMARCAD1 short isoform. The mutation, c.378þ1G>T,
was predicted to abolish the donor splice site adjacent to
the 30-end of the first unique exon of the short SMARCAD1
isoform. To confirm the existence of themutation, we used
a PCR-RFLP assay. A 537 bp long DNA fragment was ampli-
fied with the forward primer 50-AGCTGATTGGCTGGGA
ATAC-30 and reverse primer 50-GGCATTCATAAAACTCAA
AATGC-30 (Figure 3B). The mutation creates a recognition
site for MseI endonuclease (New England Biolabs, Ipswich,
MA). Using this assay, we confirmed segregation of the
mutation with the disease phenotype throughout the
entire family and also excluded the mutation from a panel
of 100 healthy Swiss individuals and 100 healthy Jewish
individuals (data not shown); this suggests that the muta-
tion does not represent a common neutral polymorphism
but rather is a disease-causing mutation.
To assess the consequences of the mutation on the
SMARCAD1-splicing pattern, we initially used RT-PCR to
amplify cDNA derived from the RNA extracted from the
fibroblast cell cultures that were established from a patient
and a healthy individual. Total RNA was extracted with
RNeasy Extraction Kit (QIAGEN). cDNA was synthesized
(Thermo Scientific Verso cDNA Synthesis Kit, ABgene,
Surrey, UK) and amplified by PCR with exon-crossing
primers, 50-GAAAGCAAGAATGTGGCAG-30; 50-GGGCTT
GAGTGACAAACT-30, located in exons 1 and 3 of the short
SMARCAD1 isoform, respectively. DNA was extracted from
gel, purified with QIAquick Gel Extraction kit (QIAGEN),
and directly sequenced as described above. Only the
wild-type splice product was identified, suggesting that
aberrant splice variants might undergo degradation. To
obtain further support for this possibility, we generated
a minigene construct17 by subcloning exon 1, parts of
intron 1 (because the first intron is very large [~10.5 kb],
we trimmed the intronic sequence) and exon 2 of the
SMARCAD1 short isoform into the pEGFP-C3 vector
(Figure 5A). More specifically, a 1.7 kb genomic DNA frag-
ment comprising exon 1 and the first 1358 bp of intron
1 was cloned into the EcoR1 and Kpn1 restriction sites of
the pEGFP-C3 vector with primers 50-AAAAAGAATTCA
AGAAATTAGAGCTTACATTTAG-30 and 50-AAAAAGGTAC
CTCACTGATTAACAGGGAAAAAG-30, respectively. Then,
a 0.7 kb genomic fragment comprising the last 500 bp of
intron 1 followed by exon 2 was cloned into the Kpn1
and BamHI sites of the first construct with primers
50-AAAAAGGTACCTATACTTTGATGATAGATGTGG-30 andan Journal of Human Genetics 89, 302–307, August 12, 2011 303
Figure 2. Genetic Mapping of ADG
(A)Multipoint LOD score analysis was performedwith the SuperLink software. LOD scores are plotted against all SNPmarkers distributed
across the genome.
(B) Haplotype analysis with polymorphic markers on chromosomal region 4q22 reveals a heterozygous 5.1Mb interval betweenmarkers
D4S423 and D4S1560 uniquely shared by all patients (boxed in red).50-AAAAGGATCCCTTTGGTTTAGAATGGAAGG-30, respec-
tively. We sequenced the entire insert to verify the authen-
ticity of the construct. Next, we introduced the
c.378þ1G>T mutation into the minigene by using the304 The American Journal of Human Genetics 89, 302–307, August 1Quick Change Site-Directed Mutagenesis kit (Stratagene,
Santa Clara, CA). Both the wild-type and the mutant mini-
gene constructs were transiently transfected into HeLa
cells with Lipofectamine 2000 (Invitrogen). Cells were2, 2011
Figure 3. Mutation Analysis
(A) Bioinformatics analysis indicated the
existence of two SMARCAD1 isoforms
differing both in lengths and sites of tran-
scription start site. The short SMARCAD1
isoform contains a unique nontranslated
exon (red arrow).
(B) Sequence analysis revealed a heterozy-
gous transversion, c.378þ1G>T, in the
short SMARCAD1 isoform (red arrow, left
panel). The wild-type sequence is given
for comparison (right panel).
(C) PCR-RFLP analysis confirmed segrega-
tion of the mutation in the family. Muta-
tion c.378þ1G>T creates a recognition
site for MseI endonuclease; thus, healthy
individuals display fragments of 163 bp
and 46 bp, whereas affected heterozygous
patients show in addition fragments of
73 bp and 90 bp.harvested 48 hr after transfection; total RNA was extracted
and subjected to RT-PCR and direct sequencing. Transfec-
tion of the wild-type minigene resulted as expected
in the formation of one single and abundant spliced
variant containing exons 1 and 2 of the short SMARCAD1
isoform; this was confirmed by sequencing analysis. In
contrast, transfection of the mutation-carrying minigeneFigure 4. Tissue Expression of SMARCAD1 Isoforms
SMARCAD1 isoform expression was assessed with Clontech tissue
blot cDNA array. Quantitative RT-PCR analysis showed that
the long SMARCAD1 isoform is expressed ubiquitously at low
level. In contrast, the short SMARCAD1 isoform was found to be
expressed mainly in skin fibroblasts, keratinocytes, and the
esophagus. Expression of SMARCAD1 was normalized to that of
ACTB. Results are provided as the fold change of expression of
SMARCAD1 long isoform expression in keratinocytes 5 standard
deviation.
The American Journal of Human Gewas found to lead to the generation
of two aberrant splice variants: the
first one was found to contain an
extra 51 bp from intron 1, and the
second one was found to miss one G
at the end of exon 1 because of theutilization of cryptic donor splice sites. Of interest, the
abnormal splice products were only marginally detectable
as compared with the wild-type RNA, both in HeLa cells
(Figure 5B) and in primary human fibroblasts (data not
shown). These results are in line with the fact that aberrant
splice variants were not detectable in patient fibroblasts
(see above).
Two main mechanisms, alone or in combination, might
explain this observation. First, authentic splicing is typi-
cally more efficient than splicing activated at cryptic
sites.18 Therefore, it is possible that the significantly
reduced level of aberrant splice variants is due to a decrease
in splicing efficiency. Another possibility is that the
abnormal 50UTR variants affect RNA stability. Indeed, alter-
ation in the secondary structure of an RNA molecule has
been shown to inhibit translation initiation directly, by
preventing the 40S subunit binding or scanning, or indi-
rectly, by preventing the action of regulatory RNA-binding
proteins. This in turn has been shown to foster mRNA
degradation by increasing decapping and the deadenyla-
tion rate.19 To assess this possibility, we initially compared
via computational analysis the secondary structure of wild-
type and aberrant splice RNA variants by using the Gene-
Bee RNA secondary-structure prediction software. As
shown in Figure 5C, computational analysis predicts that
both aberrant splice variations are likely to significantly
affect RNA secondary configuration; this prediction is in
agreement with the fact the 50UTR region of the gene
affected by the abnormal splicing is highly conserved
across species at the nucleotide level (data not shown).
To obtain experimental support for the possibility that
aberrantly spliced variants of the SMARCAD1 short isoformnetics 89, 302–307, August 12, 2011 305
Figure 5. Consequences of Mutation c.378þ1G>T
To assess the consequences of mutation c.378þ1G>Ton SMARCAD1 splicing, we used a minigene system. (A) Schematic representation
of the SMARCAD1 short isoform wild-type and mutation-carrying minigenes.
(B) Sequence analysis of RT-PCR products generated from HeLa cells transfected with wild-type and mutant minigene constructs. Trans-
fection of wild-typeminigene resulted in the formation of one spliced variant containing exons 1 and 2 of the SMARCAD1 short isoform.
In contrast, transfection of the mutant minigene resulted in two aberrant splice variants, containing an extra 51 bp from intron 1 or
missing one G at the end of exon 1. A marked decrease in the level of expression of the spliced variants was also observed.
(C) Computational modeling predicts an altered mRNA secondary structure of both aberrant splice variants.
(D) Treatment with cycloheximide (at a concentration of 50 mg/ml for 24 hr), known to inhibit mRNA decapping, resulted in signifi-
cantly increased levels of aberrant (but not wild-type) splice variants.undergo degradation, we treated cells transfected with
both the wild-type and mutation-carrying constructs
with cycloheximide at a concentration of 50 mg/ml for
24 hr, which is known to inhibit decapping of mRNA.20
As a result, we observed a significant increase in the aber-
rant splice variant levels but not in the wild-type splice
variant (Figure 5D).
In conclusion, we have identified in a large family with
ADG a splice site mutation causing aberrant splicing of
a skin-specific isoform of SMARCAD1, implicating this
gene in dermatoglyph ontogenesis. The mutation is likely
to exert a loss-of-function effect.
Little is known about the function of the full-length
SMARCAD1, and virtually nothing is known regarding
the physiological role of the skin-specific isoform of this
gene. Clearly, the tissue-specific pattern of expression of
the short isoform is likely to underlie the very limited
phenotype displayed by our patients, as attested by the
severe phenotype observed in mice knocked out for the
ubiquitous SMARCAD1 large isoform of the gene;21 those
mice feature retarded growth, perinatal mortality,
decreased fertility, and various skeletal defects.
The full-length SMARCAD1 seems to control the expres-
sion of a large spectrum of target genes encoding transcrip-306 The American Journal of Human Genetics 89, 302–307, August 1tional factors and histone modifiers as well as regulators
of the cell cycle and development.16 It is tempting to
speculate that the skin-specific isoform of SMARCAD1
might target genes involved in dermatoglyph and sweat
gland development, two structures jointly affected in
the present family and in additional disorders such as
Naegeli-Franceschetti-Jadassohn and Rapp-Hodgkin (MIM
129400) syndromes.11,22 Regardless of the exact mecha-
nisms mediating the activity of the skin-specific isoform
of SMARCAD1 in the skin, the present results once again
underscore the fact that rare monogenic traits represent
an invaluable tool for the investigation of concealed
aspects of our biology.Supplemental Data
Supplemental Data include one table and can be found with this
article online at http://www.cell.com/AJHG/.Acknowledgments
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